Blockade of Interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by Promoting Regulatory T Cells in Experimental autoimmune uveoretinitis

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 6, 2011, Pages 3264-3271

  Haruta, Hiroshi ^a,b   Ohguro, Nobuyuki ^a   Fujimoto, Minoru ^b   Hohki, Satoshi ^a,b   Terabe, Fumitaka ^b   Serada, Satoshi ^b   Nomura, Shintaro ^c   Nishida, Kohji ^a   Kishimoto, Tadamitsu ^d   Naka, Tetsuji ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c NAGAHAMA INSTITUTE OF BIO SCIENCE AND TECHNOLOGY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; CYTOKINE; EYE PROTEIN; INTERSTITIAL RETINOL-BINDING PROTEIN; RETINOL BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CERVICAL LYMPH NODE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; INFLAMMATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; UVEORETINITIS; ANIMAL; AUTOIMMUNE DISEASE; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; IMMUNOLOGY; LYMPHOCYTE DEPLETION; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; RETINITIS; SIGNAL TRANSDUCTION; UVEITIS;

ANIMALS; AUTOIMMUNE DISEASES; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE PROTEINS; INTERLEUKIN-6; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RETINITIS; RETINOL-BINDING PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; UVEITIS;

EID: 79961008060     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6272     Document Type: Article

References (39)

1. Amadi-Obi A, Yu CR, Liu X, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/ STAT1. Nat Med. 2007;13:711-718.
2. Yoshimura T, Sonoda KH, Miyazaki Y, et al. Differential roles for IFN-gamma and IL-17 in experimental autoimmune uveoretinitis. Int Immunol. 2008;20:209-214.
3. Bettelli E, Oukka M, Kuchroo VK. TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8:345-350.
4. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429-442.
5. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133-1141.
6. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGF-beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179-189.
7. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235-238.
8. Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-β induces development of the T(H)17 lineage. Nature. 2006;441:231-234.
9. +regulatory T cells. Proc Natl Acad Sci U S A. 2008;105:18460-18465.
10. Fujimoto M, Serada S, Mihara, et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum. 2008;58:3710-3719.
11. Serada S, Fujimoto M, Mihara M, et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2008;105:9041-9046.
12. Yoshimura T, Sonoda KH, Ohguro N, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford). 2009;48:347-354.
13. Hohki S, Ohguro N, Haruta H, et al. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp Eye Res. 2010; 91:162-170.
14. Tarrant TK, Silver PB, Chan CC, Wiggert B, Caspi RR. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis. J Immunol. 1998;161:122-127.
15. Xu H, Rizzo LV, Silver PB, Caspi RR. Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis. Cell Immunol. 1997;178:69-78.
16. Jones LS, Rizzo LV, Agarwal RK, et al. IFN-γ-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J Immunol. 1997;158:5997-6005.
17. Fukushima A, Yamaguchi T, Ishida W, Fukata K, Udaka K, Ueno H. Mice lacking the IFN-γ receptor or fyn develop severe experimental autoimmune uveoretinitis characterized by different immune responses. Immunogenetics. 2005;57:337-343.
18. Luger D, Silver PB, Tang J, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med. 2008;205:799-810.
19. +interphotoreceptor retinoid-binding protein-specific T cells in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 2007;48:4153-4161.
20. Diehl S, Anguita J, Hoffmeyer A, et al. Inhibition of Th1 differentiation by Il-6 is mediated by SOCS1. Immunity. 2003;13:805-815.
21. Diehl S, Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol. 2002;39:531-536.
22. Horino J, Fujimoto M, Terabe F, et al. Suppressor of cytokine signaling-1 ameliorates dextran sulfate sodium-induced colitis in mice. Int Immunol. 2008;20:753-762.
23. Thurau SR, Diedrichs-Mohring M, Fricke H, Burchardi C, Wildner G. Oral tolerance with an HLA-peptide mimicking retinal autoantigen as a treatment of autoimmune uveitis. Immunol Lett. 1999; 68:205-212.
24. Alegre ML, Noel PJ, Eisfelder BJ, et al. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol. 1996;157:4762-4770.
25. +T cells exacerbates experimental autoimmune encephalomyelitis induced by mouse, but not rat, antigens. J Neurosci Res. 2009;87:3511-3519.
26. +regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9:239-244.
27. +regulatory T cells in autoimmune diseases. Nat Clin Pract Rheumatol. 2007;3:619-626.
28. +regulatory T cells suppresses experimental autoimmune uveoretinitis. Br J Ophthalmol. 2007;91:105-110.
29. +T regulatory cells induced by LPS-activated bone marrow dendritic cells suppress experimental autoimmune uveoretinitis in vivo. Graefe's Arch Clin Exp Ophthalmol. 2007;245: 221-229.
30. +T cells to the regression phase of experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2010;51:383-389.
31. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky A. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005;6:1142-1151.
32. +regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol. 2005;6:1152-1159.
33. +regulatory T cells. Eur J Immunol. 2008;38:1643-1653.
34. +regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells. Cell Res. 2007;17: 627-637.
35. Li B, Yang P, Zhou H, et al. Upregulation of T-bet expression in peripheral blood mononuclear cells during Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2005;89:1410-1412.
36. Zhao C, Yang P, He H, et al. S-antigen specific T helper type 1 response is present in Behçet's disease. Mol Vis. 2008;14:1456-1464.
37. Liu X, Yang P, Lin X, et al. Inhibitory effect of cyclosporin A and corticosteroids on the production of IFN-γ and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome. Clin Immunol. 2009;131:333-342.
38. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817-2829.
39. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761-1769.